170 related articles for article (PubMed ID: 28254655)
1. Real life dose emission characterization using COPD patient inhalation profiles when they inhaled using a fixed dose combination (FDC) of the medium strength Symbicort
Bagherisadeghi G; Larhrib EH; Chrystyn H
Int J Pharm; 2017 Apr; 522(1-2):137-146. PubMed ID: 28254655
[TBL] [Abstract][Full Text] [Related]
2. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH
Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254
[TBL] [Abstract][Full Text] [Related]
3. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.
Cazzola M; Ora J; Di Paolo A; Puxeddu E; Calzetta L; Rogliani P
Pulm Pharmacol Ther; 2016 Aug; 39():48-53. PubMed ID: 27344046
[TBL] [Abstract][Full Text] [Related]
4. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
Chrystyn H; Safioti G; Keegstra JR; Gopalan G
Int J Pharm; 2015 Aug; 491(1-2):268-76. PubMed ID: 26043823
[TBL] [Abstract][Full Text] [Related]
5. Budesonide + formoterol delivered via Spiromax
Lewis A; Torvinen S; Dekhuijzen PNR; Chrystyn H; Melani A; Zöllner Y; Kolbe K; Watson AT; Blackney M; Plich A
Respir Med; 2017 Aug; 129():179-188. PubMed ID: 28732829
[TBL] [Abstract][Full Text] [Related]
6. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.
Azouz W; Chetcuti P; Hosker H; Saralaya D; Chrystyn H
BMC Pulm Med; 2015 May; 15():47. PubMed ID: 25927483
[TBL] [Abstract][Full Text] [Related]
7. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
[TBL] [Abstract][Full Text] [Related]
8. Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.
Farkas Á; Jókay Á; Balásházy I; Füri P; Müller V; Tomisa G; Horváth A
Eur J Pharm Sci; 2016 Oct; 93():371-9. PubMed ID: 27552906
[TBL] [Abstract][Full Text] [Related]
9. The inhalation characteristics of patients when they use different dry powder inhalers.
Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
[TBL] [Abstract][Full Text] [Related]
10. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.
Voorham J; Roche N; Benhaddi H; van der Tol M; Carter V; van Boven JFM; Bjermer L; Miravitlles M; Price DB
BMJ Open; 2018 Oct; 8(10):e022051. PubMed ID: 30368448
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
13. Optimal Inhalation Flow Pattern from Turbuhaler Predicted by Laser Photometry.
Kondo T; Hibino M; Tanigaki T; Tajiri S; Horiuchi S
J Aerosol Med Pulm Drug Deliv; 2022 Jun; 35(3):139-145. PubMed ID: 34637629
[No Abstract] [Full Text] [Related]
14. Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler.
Lähelmä S; Sairanen U; Haikarainen J; Korhonen J; Vahteristo M; Fuhr R; Kirjavainen M
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):462-73. PubMed ID: 25757188
[TBL] [Abstract][Full Text] [Related]
15. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics.
Tarsin WY; Pearson SB; Assi KH; Chrystyn H
Int J Pharm; 2006 Jun; 316(1-2):131-7. PubMed ID: 16584855
[TBL] [Abstract][Full Text] [Related]
16. Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler.
Abadelah M; Chrystyn H; Larhrib H
Eur J Pharm Sci; 2019 Jun; 134():138-144. PubMed ID: 31005623
[TBL] [Abstract][Full Text] [Related]
17. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
19. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study.
Janson C; Lööf T; Telg G; Stratelis G; Nilsson F
NPJ Prim Care Respir Med; 2016 Nov; 26():16053. PubMed ID: 27853177
[TBL] [Abstract][Full Text] [Related]
20. The dry powder inhaler features of the Easyhaler that benefit the management of patients.
Chrystyn H; Lavorini F
Expert Rev Respir Med; 2020 Apr; 14(4):345-351. PubMed ID: 32013627
[No Abstract] [Full Text] [Related]
[Next] [New Search]
